The antigenic peptide construct:

• Has no homology to its HSV-l counterpart;
• Its use eliminates cross reactivity between HSV- 1 and HSV-2.
• Is highly immunogenic, thus rendering it an ideal marker for HSV-2, as distinct from HSV- 1.

This assay incorporates a design to determine whether the patient has ever been infected with HSV-l and to differentiate between infection with HSV-l and HSV-2. 

AuRx believes that this assay will be widely accepted in the marketplace because it can be carried out with a very small amount of blood, can be easily performed in a non-laboratory setting such as a doctor's office and, equally important, generates results within 5 to 10 minutes. 

US Patent: 5,919,616 Serological assay for herpes